Canagliflozin reduced kidney failure and CV events at 2.6 years in type 2 diabetes with chronic kidney disease
Sodium–glucose cotransporter 2 inhibitors appear to be a promising treatment option for patients with diabetes and chronic kidney disease, according to an ACP Journal Club commentary.
13 Sep 2019
In uncontrolled type 2 diabetes, adjunctive semaglutide reduced HbA1c and body weight vs sitagliptin
The trial showed that an oral glucagon-like peptide-1–receptor analogue improved glycemic control compared to a dipeptidyl peptidase 4 inhibitor, but gastrointestinal side effects and cost remain barriers to use of the former class.
13 Sep 2019
A commentary reviewed the findings of REWIND, PIONEER 6, and PIONEER 4 trials, which studied the cardiovascular and glycemic control effects of dulaglutide, semaglutide, and liraglutide.
11 Oct 2019
The positive results of a trial of continuous glucose monitoring in type 1 diabetes patients ages 60 years and older support recommending the technology to this group, according to an ACP Journal Club commentary.
11 Dec 2020
An ACP Journal Club commentary recommends advising patients with type 2 diabetes who don't smoke and who take metformin to also consider increasing their soluble fiber intake by more than 10 g/d.
14 Jun 2019
In type 2 diabetes with periodontitis, intensive periodontitis treatment improved glycemic control at 1 year
Putting these findings into practice may require incorporating dental professionals into diabetes care teams and training clinicians who treat patients with diabetes to recognize and assess periodontal disease and make appropriate referrals, the ACP Journal Club commentary said.
10 May 2019
Review: Rapid-acting analogues do not differ from regular human insulin for mortality or HbA1c in type 2 diabetes
The review shows that, contrary to specialty recommendations, there is no reason not to use regular human insulins, which are less costly than analogue insulins, said an ACP Journal Club commentary.
10 May 2019
An ACP Journal Club commentary looked at studies on the effects of canagliflozin in patients with cardiovascular disease and dapagliflozin in patients with peripheral artery disease, concluding that amputation risks are small enough that they needn't play a major role in prescribing decisions.
12 Feb 2021
In stable CAD with type 2 diabetes, adding ticagrelor to aspirin reduced CV events but increased major bleeding
Although an industry-funded trial found little net benefit overall from adding ticagrelor to aspirin, it's possible that some patients with higher ischemic risk and low bleeding risk could benefit, according to an ACP Journal Club commentary.
14 Feb 2020
In diabetes with no CVD, aspirin reduced serious vascular events but increased major bleeding at 7.4 years
The results of a recent trial of aspirin for cardiovascular disease (CVD) prevention in diabetes challenge current guidelines and the opinion of many clinicians of the net benefit of the drug, according to an ACP Journal Club commentary.
11 Jan 2019